🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the effort against superbug strains of the pathogen, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting over 82 million new cases each year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the very limited treatment choices presently on offer.”

Health officials are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists hope that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in close succession. This treatment, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

According to results detailed in a major medical journal, zoliflodacin cured over nine in ten of cases of the STI. This places it at an equal footing with the current standard treatment, which uses two antibiotics. The research included hundreds of participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have expressed optimism. The availability of a single-dose, oral treatment such as this is described as a "game-changer" for public health efforts. This is deemed essential to lessen the impact of the infection for people and to halt the transmission of untreatable gonorrhoea around the world.